Last reviewed · How we verify

NCT03315403: CAPTAIN

Quantitative Polymerase Chain Reaction for Improved Detection of Pneumococci in CAP "CAPTAIN"

Completed Last updated 8 April 2022
What this trial tests

trial testing LytA targeted quantitative polymerase chain reaction (qPCR) in Pneumonia, Pneumococcal in 922 participants. Completed in 12 March 2020.

Timeline
5 April 2018
Primary endpoint
12 March 2020
12 March 2020

Quick facts

Lead sponsorMedical Center Alkmaar
StatusCompleted
Study typeOBSERVATIONAL
Enrollment922
Start date5 April 2018
Primary completion12 March 2020
Estimated completion12 March 2020
Sites2 locations across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Medical Center Alkmaar

Who can join

18 and older, any sex, with Pneumonia, Pneumococcal or Community-acquired Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the added diagnostic value of a quantitative polymerase chain reaction targeting the lytA gene in detecting pneumococci in patients with community-acquired pneumonia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Medical Center Alkmaar trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03315403.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing